Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer
暂无分享,去创建一个
S. Steinberg | A. Chen | J. Schlom | W. Dahut | J. Gulley | D. Poole | K. Tsang | D. Panicali | A. Bastian | P. Arlen | J. Michael Hamilton
[1] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[2] J. Schlom,et al. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. , 2001, Cancer research.
[3] J. Schlom,et al. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. , 2001, Cancer research.
[4] E. Gehan,et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Steinberg,et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines , 2000, Cancer Immunology, Immunotherapy.
[6] G. Weiner,et al. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development , 2000, Current opinion in hematology.
[7] P. Kantoff,et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] J. Schlom,et al. A triad of costimulatory molecules synergize to amplify T-cell activation. , 1999, Cancer research.
[9] J. Schlom,et al. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. , 1999, Vaccine.
[10] K. Pienta,et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. , 1999, Urology.
[11] J. Schlom,et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. , 1998, Journal of immunology.
[12] S. Rosenberg,et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.
[13] J. Schlom,et al. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. , 1997, Vaccine.
[14] J. Schlom,et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. , 1997, Journal of the National Cancer Institute.
[15] H. Rammensee,et al. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] A. García-Sastre,et al. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. , 1996, Cellular immunology.
[17] R. Barth,et al. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes , 1996, Cancer Immunology, Immunotherapy.
[18] J. Schlom,et al. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. , 1996, Cancer research.
[19] J. Schlom,et al. A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate , 1995, International journal of cancer.
[20] J. Schlom,et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.